CrossrefInfokarteTargeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage
Saumya Ranjan Satrusal, Arpita Banerjee, Arpon Biswas, Gaurava Srivastava, Indranil Chatterjee, Muqtada Ali Khan, Biswajit Mandal, Kiran Tripathi, Abhipsa Sinha, Ayushi Verma, Priyanka Rai, Mahmood Akbar, Shivansh Kumar, Sohini Chatterjee, Kulranjan Singh, Aamir Nazir, Rabi Sankar Bhatta, Gautam Panda, Dipak Datta
Molecular Therapy · 2026-11 · 34 (11) · 6513-6560
DOI: 10.1016/j.ymthe.2026.08.034 ↗